| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Imatinib D8 targets the same kinases as Imatinib, including BCR/ABL, v-Abl, PDGFR, and c-kit. As a deuterium-labeled analogue, it retains the pharmacological activity of Imatinib. The primary use of Imatinib D8 is as an analytical internal standard for quantifying Imatinib in biological samples. Its deuterium labeling allows for differentiation from unlabeled Imatinib in mass spectrometry.
|
|---|---|
| ln Vitro |
In vitro, Imatinib D8 exhibits the same kinase inhibitory activity as Imatinib. It inhibits BCR/ABL, v-Abl, PDGFR, and c-kit kinase activity. However, the compound is primarily used as an analytical standard rather than for biological activity studies. Its activity is measured in kinase assays. The deuterium labeling does not significantly affect its biological activity.
|
| ln Vivo |
In vivo, Imatinib D8 is not typically used for therapeutic purposes but as an internal standard for pharmacokinetic studies. Its behavior in vivo is similar to Imatinib. The compound is used to quantify Imatinib levels in plasma and tissues. Its deuterium labeling allows for accurate quantification by mass spectrometry. It is used in pharmacokinetic and bioavailability studies.
|
| Enzyme Assay |
The cell-free assay for Imatinib D8 involves its use as an internal standard in analytical chemistry. The compound is added to biological samples at known concentrations. Samples are extracted and analyzed by LC-MS/MS. The ratio of Imatinib to Imatinib D8 is used to calculate the concentration of Imatinib. The compound's chemical purity is confirmed by HPLC.
|
| Cell Assay |
For in vitro cellular assays, Imatinib D8 is not typically used in biological assays. Its primary application is as an analytical standard. The compound may be used in cell culture studies to assess Imatinib uptake and metabolism. Its deuterium labeling allows for tracking of the compound in cells.
|
| Animal Protocol |
In vivo animal studies for Imatinib D8 are conducted as part of pharmacokinetic studies. The compound is administered to animals, and blood and tissue samples are collected. Samples are analyzed by LC-MS/MS using Imatinib D8 as an internal standard. Pharmacokinetic parameters such as half-life, Cmax, and AUC are determined. The compound's behavior is used to quantify Imatinib pharmacokinetics.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Imatinib D8 include a molecular weight of 501.65 g/mol and molecular formula C29H31N7O. The compound has a purity of 98% with 98% atom% D. As a deuterium-labeled analogue, its pharmacokinetics are similar to Imatinib. It is typically stored at appropriate conditions as a reference standard. The compound is used for analytical method development and quality control.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Imatinib D8 is expected to be similar to Imatinib. Imatinib has a well-characterized safety profile. The compound is intended for research and analytical use only and not for therapeutic applications. Standard safety precautions should be followed when handling this compound.
|
| References |
|
| Additional Infomation |
Imatinib D8 is a deuterium-labeled analogue of Imatinib (STI571), a tyrosine kinase inhibitor that inhibits BCR/ABL, v-Abl, PDGFR, and c-kit. It is intended for use as an internal standard for the quantification of Imatinib by GC- or LC-mass spectrometry. Imatinib D8 is used for analytical method development, quality control, and pharmacokinetic studies. The compound is a research and analytical tool, not a therapeutic agent.
|
| Molecular Formula |
C29H23D8N7O
|
|---|---|
| Molecular Weight |
501.65200
|
| Exact Mass |
501.309
|
| CAS # |
1092942-82-9
|
| Related CAS # |
Imatinib;152459-95-5
|
| PubChem CID |
25235773
|
| Appearance |
White to light yellow solid powder
|
| Melting Point |
96-100 °C
|
| LogP |
4.612
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
37
|
| Complexity |
706
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C1(C(N(C(C(N1C)([2H])[2H])([2H])[2H])CC2=CC=C(C=C2)C(=O)NC3=CC(=C(C=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5)([2H])[2H])[2H]
|
| InChi Key |
KTUFNOKKBVMGRW-AZGHYOHESA-N
|
| InChi Code |
InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)/i14D2,15D2,16D2,17D2
|
| Chemical Name |
N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-4-[(2,2,3,3,5,5,6,6-octadeuterio-4-methylpiperazin-1-yl)methyl]benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9934 mL | 9.9671 mL | 19.9342 mL | |
| 5 mM | 0.3987 mL | 1.9934 mL | 3.9868 mL | |
| 10 mM | 0.1993 mL | 0.9967 mL | 1.9934 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
